Business
Milestone Scientific Launches CompuFlo® Advisor Program to Accelerate Commercial Adoption and Drive Utilization Growth in Select MAC Jurisdictions; Plans National Expansion
ROSELAND, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced the launch of the CompuFlo® Advisor Program. This strategic initiative is designed to drive mainstream commercial adoption, increase recurring disposable revenue, and generate the clinical data necessary to optimize long-term Medicare reimbursement rates. The program, which commen
About this update from Milestone Scientific, Inc.
[{"type":"image","alt":"Milestone Scientific, Inc.","displaySize":"","headline":null,"caption":"Milestone Scientific, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":65,"url":"https://media.zenfs.com/en/globenewswire.com/2153125b7314814c812953238fb1ca11"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/exjbRkdU8va83bSGZUweuQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/2153125b7314814c812953238fb1ca11","width":300,"height":65}},"lazy":false},{"type":"text","content":"ROSELAND, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced the launch of the CompuFlo® Advisor Program. This strategic initiative is designed to drive mainstream commercial adoption, increase recurring disposable revenue, and generate the clinical data necessary to optimize long-term Medicare reimbursement rates.","length":474,"tagName":"p"},{"type":"text","content":"The program, which commenced on February 1, 2026, targets high-volume interventional pain and anesthesia practices within key Medicare Administrative Contractor (MAC) jurisdictions, including Novitas, First Coast, Noridian, and Palmetto. These jurisdictions represent a strategic first phase of execution, with infrastructure designed to support phased expansion across additional MAC regions throughout the United States. By engaging Key Opinion Leaders (KOLs) to generate a targeted 1,000–2,000 case submissions in the initial six-month phase, Milestone is executing a structured clinical and reimbursement roadmap to transition CPT® code 0777T from Category III to Category I status, that could enhance commercial adoption and long-term revenue visibility.","length":759,"tagName":"p"},{"type":"text","content":"To ensure the program delivers a scalable recurring revenue model, Milestone has deployed a robust commercial infrastructure designed to support national expansion. The Company has also engaged industry veterans, including Evelyn Gittinger, CPC, and Neuro Management Solutions (NMS), to provide real-time claims support, documentation guidance, and payer advocacy.","length":364,"tagName":"p"},{"type":"text","content":""The Advisor Program is a key strategic initiative for Mil...